Fortress Biotech Inc. (FBIO)
NASDAQ: FBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FBIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $64.11M
- P/E (TTM)
- 0.83
- EPS (TTM)
- $2.30
- Dividend yield
- None
- 52-week range
- 1.64 – 4.53
- Day range
- 1.84 – 1.99
- Volume / Avg
- 739.06K / 281.49K
- Beta
- —
- Shares outstanding
- 33.74M
52-week range
FBIO stock today
Fortress Biotech (FBIO) closed at $1.90 on Nov 20, up 7.34% (+$0.13), versus the S&P 500's 3.70% decline. Volume was 2.6x the average at 739.06K shares, a sign of unusually heavy trading. At this level, FBIO sits near the bottom of its 52-week range of $1.64 to $4.53: 58.1% below the high, set on Jan 9, 2026 and 15.9% above the low.
FBIO is down 48.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 26.6%. Fortress Biotech trades at 0.8x its trailing twelve-month earnings per share of $2.30.
Summary generated from market data by MetaCap's automated system. Methodology
About Fortress Biotech
Company profileFortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Lindsay Allan Rosenwald M.D.
- Headquarters
- Bay Harbor Islands, FL
- Employees
- 78
- Website
- fortressbiotech.com
Financial highlights
Full financialsIn fiscal 2025, Fortress Biotech generated $63.3 million in revenue, up 9.7% from fiscal 2024. Net income was $6.8 million, for a net margin of 10.8% versus a median of -94.1% in the prior 5 years. Gross margin was 66.9% (up from 63.8%) and operating margin -111.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $63.26M | $57.67M | $84.51M | $75.74M | $68.79M |
| Growth | +9.69% | -31.76% | +11.58% | +10.11% | +50.86% |
| Net income | $6.82M | $-46.00M | $-60.64M | $-86.58M | $-64.70M |
| EPS (diluted) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$5.00+163.16%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.23 vs —
FBIO news
All FBIO news- Fortress Biotech: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Fortress Biotech (FBIO) Q3 2026 Earnings Call TranscriptNasdaq
- Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswire
- Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireDERM, FBIO
- Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026GlobeNewswireDERM, FBIO
Fortress Biotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GOSSGossamer Bio Inc. | 10.72 | -4.54% | $65.57M | vs FBIO |
| VTVTvTv Therapeutics Inc. Class A | 15.51 | -5.20% | $62.22M | vs FBIO |
| PMVPPMV Pharmaceuticals Inc. | 0.876 | -33.13% | $66.17M | vs FBIO |
| PLYXPolaryx Therapeutics Inc. | 1.33 | -11.92% | $66.30M | vs FBIO |
| MNOVMedicinova Inc | 1.31 | +3.15% | $67.11M | vs FBIO |
| CINGCingulate Inc. | 4.51 | -14.26% | $67.48M | vs FBIO |
| MAIAMAIA Biotechnology Inc. | 1.11 | -2.63% | $68.54M | vs FBIO |
| RANIRani Therapeutics Holdings Inc. Class A | 0.5111 | -11.97% | $59.03M | vs FBIO |
Indexes, lists and sector
Fortress Biotech stock FAQ
What is Fortress Biotech's stock price today?
FBIO last traded at $1.90 as of Nov 20, 4:00 PM EST, up 7.34% on the day. Prices are delayed at least 15 minutes.
Does Fortress Biotech pay a dividend?
No. Fortress Biotech does not currently pay a regular cash dividend.
What is FBIO's P/E ratio?
FBIO trades at a trailing P/E ratio of 0.83.
Who is Fortress Biotech's CEO?
Dr. Lindsay Allan Rosenwald M.D. is the chief executive officer of Fortress Biotech Inc., which has about 78 employees.
Has FBIO ever split its stock?
Yes. The most recent FBIO stock split was a 1-for-15 split on Oct 10, 2023.
What is the FBIO 52-week high?
The 52-week high for FBIO is $4.53 and the 52-week low is $1.64. The stock is currently 58.1% below its high.